Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen
| Autor: | Roy Mackintosh, Nashat Y. Gabrail, Haresh S. Jhangiani, Robert Vescio, Alberto Bessudo, Ashkan Lashkari, James R. Berenson, Tanya M. Spektor, Michael Oren Robinson, Tina Maluso, Regina A. Swift, Samir V. Kubba, Jeffrey D. Neidhart, Alexa Cohen, Ibrahim Nakhoul |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty business.industry Immunomodulatory drug Refractory Multiple Myeloma Pomalidomide medicine.disease 03 medical and health sciences Regimen 0302 clinical medicine Refractory 030220 oncology & carcinogenesis Internal medicine Relapsed refractory medicine business Multiple myeloma 030215 immunology medicine.drug Lenalidomide |
| Zdroj: | Journal of Clinical Oncology. 36:e20012-e20012 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | e20012Background: Pomalidomide (POM) is a third–generation immunomodulatory drug shown to be safe and effective for the treatment of relapsed/refractory multiple myeloma (RRMM) patients (pts) previ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|